Biotechnology solutions for therapeutics discovery and development
Creative Biolabs is a US-based biotechnology company that provides integrated research services and customised solutions to pharmaceutical, biotechnology, and academic organisations worldwide. Its core capabilities include antibody discovery and engineering, phage display, engineered antibodies, CAR-T and other cell therapies, gene therapy development, drug delivery, animal disease models, and preclinical research. Through multidisciplinary expertise and established technology platforms, Creative Biolabs supports therapeutic programmes from early discovery and candidate generation through functional characterisation and preclinical evaluation.
Phage display and antibody discovery services
Creative Biolabs provides comprehensive phage display services for antibody and peptide discovery. Capabilities include custom phage display library construction, library screening, binder identification, and downstream antibody development. Screening workflows can be tailored to target properties, desired binder characteristics, and project-specific research objectives.
The platform also supports specialised discovery programmes for PTM-specific antibodies, anti-idiotype antibodies, agonistic antibodies, and peptidome discovery. By connecting library design and construction with screening and subsequent antibody development, researchers can use individual capabilities or assemble a coordinated discovery workflow for biologics research.
Engineered antibody development services
For researchers developing next-generation biologics, Creative Biolabs offers a broad range of engineered antibody services. These include bispecific antibody development, antibody-drug conjugate (ADC) development, immune checkpoint antibody development, and customised antibody formats designed around specific research needs.
Creative Biolabs provides integrated antibody discovery, engineering, characterisation and ADC development solutions to advance differentiated therapeutic candidates toward preclinical evaluation.
Creative Biolabs delivers immuno-oncology and engineered cell therapy solutions covering target validation, CAR design, immune-cell engineering, functional assays and preclinical evaluation.
Creative Biolabs offers stem cell and iPSC solutions spanning reprogramming, expansion, directed differentiation, characterization, disease modelling and cell therapy research.
Creative Biolabs supports gene therapy development through vector design, production, purification, characterisation and delivery optimisation for diverse preclinical applications.
Creative Biolabs provides integrated mRNA and LNP services covering sequence design, synthesis, formulation, characterisation, delivery optimisation and preclinical evaluation.
Creative Biolabs supports vaccine development with antigen design, formulation, immunogenicity assessment, efficacy studies and preclinical evaluation across multiple vaccine platforms.
Creative Biolabs combines disease-relevant neural models, blood–brain barrier systems, functional assays and biomarker analysis to support neuroscience drug discovery.
Creative Biolabs develops organoids, spheroids and organ-on-chip models for more predictive evaluation of drug efficacy, toxicity and disease mechanisms.
Creative Biolabs provides glycoprotein development and glycoengineering services encompassing protein production, glycan modification, structural characterisation and functional optimisation.
Creative Biolabs supplies high-quality NHP tissues, fluids, cells and lysates for translational research, biomarker studies and preclinical assay development.
Engineered antibody programmes can connect with antibody discovery, characterisation, optimisation, and preclinical evaluation. This flexible structure enables researchers to address different stages of antibody R&D within a coordinated service framework while selecting the technologies most relevant to the target, mechanism, and intended experimental strategy.
CAR-T and engineered cell therapy development
Creative Biolabs has established platforms for engineered immune cell therapy research. Its CAR-T therapy development services cover multiple stages of preclinical development, including CAR construct design, vector development, engineered cell generation, and functional evaluation. Related capabilities include one-stop CAR-T therapy development, TCR-modified T-cell development, CAR-macrophage (CAR-M) therapy development, and canine CAR-T therapy development.
Research products also support CAR/TCR programmes, including CAR and TCR vectors, engineered cells and animal cells, and development kits. Researchers can access individual products and services or combine multiple capabilities according to the design and stage of an engineered cell therapy programme.
Gene therapy development and delivery solutions
Creative Biolabs provides integrated gene therapy development services for researchers advancing genetic therapeutics. The platform covers important areas of preclinical gene therapy development, including delivery vehicle development, potency testing, safety and toxicology assessment, and disease-specific development solutions.
Programmes can be customised according to therapeutic modality, target, delivery strategy, and study objectives. By bringing together delivery, biological activity assessment, and preclinical evaluation capabilities, Creative Biolabs supports researchers addressing technical challenges as gene therapy candidates progress from concept to more advanced preclinical studies.
Animal disease models and preclinical research
Preclinical models are essential for investigating therapeutic efficacy, pharmacology, pharmacokinetics/pharmacodynamics (PK/PD), safety, and translational potential. Creative Biolabs provides a diverse portfolio of animal disease models for pharmaceutical and biotechnology research, including genetically engineered models (GEMs), knockout, knock-in, and knockdown models, humanised mouse models, rodent tumour models, and non-human primate (NHP) disease models.
Custom animal model development is available for studies requiring specific disease phenotypes, genetic backgrounds, or experimental designs. These models can be incorporated into efficacy, pharmacology, PK/PD, and other preclinical studies, helping researchers generate data for therapeutic candidate characterisation and development decisions.
Flexible support from discovery to preclinical development
Therapeutic development often requires coordinated expertise across multiple technologies. Creative Biolabs brings together specialised platforms in antibody discovery and engineering, cell therapy, gene therapy, drug delivery, and preclinical research so that clients can select standalone services for defined experimental needs or combine complementary capabilities into broader development programmes.
Rather than applying a single standardised workflow, project strategies can be developed around research stage, technical requirements, and R&D objectives. This service model is designed to give pharmaceutical, biotechnology, and academic researchers practical flexibility as programmes evolve and new experimental questions emerge.
Advancing therapeutic research with Creative Biolabs
Creative Biolabs continues to expand its biotechnology platforms and scientific capabilities to address evolving needs in drug discovery and preclinical development. Across antibody discovery, engineered biologics, cell therapy, gene therapy, delivery, and animal research, the company provides customisable research support to help clients advance therapeutic concepts toward subsequent development stages.
To discuss a project or identify suitable research services, contact Creative Biolabs or explore its technology platforms online to build a customised development strategy aligned with your programs.
Cell therapy is entering a phase where operational efficiency is becoming as decisive as scientific novelty. Autologous CAR-T has demonstrated clinical power, but the logistical bottlenecks of vein-to-vein orchestration create unavoidable friction. For programmes aiming for late-stage scalability, this friction becomes a commercial non-starter. Creative Biolabs summarises actionable efficiency levers for CAR-NK and iPSC-derived immune cell programmes.
Solid tumours are not “harder blood cancers.” They are engineered ecosystems—mechanically fortified, metabolically hostile, and immunologically suppressive. Next-gen CAR-T success depends on designing for the ecosystem, not just the antigen.
Creative Biolabs provides integrated antibody discovery and development services to support pharmaceutical, biotechnology and academic research programmes.
The development of effective cancer immunotherapies requires a clear understanding of tumour biology, immune-cell function and the mechanisms that limit antitumour responses.
Creative Biolabs provides customised stem cell and induced pluripotent stem cell (iPSC) services for pharmaceutical, biotechnology and academic research programmes.
Creative Biolabs provides customised research services for viral and non-viral gene delivery programmes, supporting projects from construct design through in vitro characterisation and preclinical evaluation.
The performance of an mRNA therapeutic depends on both the RNA molecule and the delivery system. Sequence architecture affects stability and protein expression, while formulation influences cargo protection, cellular uptake, biodistribution and tolerability. Creative Biolabs provides integrated mRNA and lipid nanoparticle development services, from construct design and in vitro transcription to formulation optimisation and preclinical evaluation.
Vaccine development requires alignment between antigen design, delivery platform, formulation and the immune response needed for protection or therapeutic activity. Decisions made at the discovery stage can influence antigen stability, epitope presentation, manufacturability and performance in later studies. Creative Biolabs provides research services supporting vaccine programmes from target and antigen selection through formulation and preclinical evaluation.
Neurological drug development often fails because early models do not reproduce the human biology that drives disease or measure outcomes that translate to later studies. A useful model must reflect the relevant cell population, genetic background and disease mechanism while remaining sufficiently reproducible for candidate comparison. Creative Biolabs develops neuroscience research programmes that connect human cell models, functional assays, blood–brain barrier studies and preclinical evaluation.
Conventional monolayer cultures remain useful for many assays, but they cannot fully reproduce the spatial organisation, cellular diversity and local microenvironment of living tissues. Three-dimensional models provide an intermediate level of biological complexity between standard cell culture and in vivo studies, helping researchers investigate drug responses in a more tissue-relevant setting.
Glycosylation can influence the folding, stability, solubility, receptor interactions, serum persistence and immune effector functions of a therapeutic protein. It also introduces structural heterogeneity that must be understood when comparing expression systems, production conditions or candidate molecules. Creative Biolabs provides glycoprotein development, glycan analysis and glycoengineering services for antibodies, recombinant proteins, enzymes, vaccine antigens and other biologics.
Non-human primate biological materials are used in research because of their physiological, immunological and genetic similarities to humans. They can provide relevant matrices for assay development, biomarker research, pharmacology and comparative biology when human samples are unavailable or when cross-species evaluation is required.
